<DOC>
	<DOCNO>NCT03065010</DOCNO>
	<brief_summary>A Multicenter Open-label Non-comparative 2-Stage Phase 1a/1b Study Assess Safety Pharmacokinetics Oral BCD-115 ( JSC BIOCAD , Russia ) Combination Endocrine Therapy Women ER ( + ) HER2 ( - ) Local Advanced Metastatic Breast Cancer</brief_summary>
	<brief_title>Study BCD-115 Women With ER ( + ) HER2 ( - ) Local Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>Multicentre dose-finding open-label non-comparative phase Ia/Ib clinical trial investigation safety , tolerability , pharmacokinetics BCD-115 administer p.o . intrapatient dose escalation population patient ER ( + ) HER2 ( - ) advance breast cancer combination standard dose endocrine therapy . The trial conduct two stage : Stage 1 - find maximum tolerate dose , determination recommend dose Stage 2 . Stage 2 - study recommend dose Stage 1 BCD-115 , analysis tolerability safety select dose/doses additional cohort , determination estimate therapeutic dose/doses clinical study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Written inform consent ability follow Protocol procedure ; 2 . Age ≥18 year ; 3 . Female gender ; 4 . Postmenopausal status ( Prior bilateral surgical oophorectomy ; medically confirm postmenopausal status define spontaneous cessation regular menses least 12 consecutive month alternative pathological physiological cause ) ; 5 . Histologically proven diagnosis adenocarcinoma breast evidence metastatic disease ; 6 . Progression advance breast cancer first line endocrine therapy advance breast cancer . 7 . ER positive tumor ≥ 10 % ; 8 . HER2 negative breast cancer FISH IHC ; 9 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 10 . Measurable disease accord RECIST 1.1 ( bone disease allow ) 11 . Resolution acute toxic effect prior therapy ( include endocrine therapy ) surgical procedure CTCAE grade ≤1 12 . Adequate organ function ; 13 . Life expectancy 12 week moment randomization 1 . HER2positive tumour ; 2 . Patients unstable brain metastasis , advance , symptomatic , visceral spread disease , risk lifethreatening complication short term ( include patient massive uncontrolled effusion pleural , pericardial , peritoneal , pulmonary lymphangitis , 50 % liver involvement ) . 3 . Important cardiovascular event past 6 month randomization ; 4 . GI diseases may affect absorption study drug ; 5 . Inadequate hematopoietic function : neutrophil ≤1500/mm3 , platelet ≤100 000/mm3 , hemoglobin ≤90 g/L ; 6 . Inadequate renal function : creatinine level ≥ 1.5 × upper limit normal ( ULN ) ; 7 . Inadequate liver function : bilirubin level ≥ 1.5 × ULN , AST ALT level ≥ 2.5 × ULN ( 5 × ULN patient liver metastasis ) , alkaline phosphatase level ≥ 5 × ULN ; 8 . Concurrent antitumor treatment 21 day randomization ( surgery , radiation therapy ; chemotherapy , except endocrine therapy ) ; 9 . Any concomitant cancer include contralateral breast cancer reveal within 5 year prior screen , except curatively treat intraductal carcinoma situ , curatively treated cervical carcinoma situ curatively treat basal cell squamous cell carcinoma ; 10 . Conditions limit patient 's adherence protocol requirement ( dementia , neurologic psychiatric disorder , drug addiction , alcoholism others ) ; 11 . Concomitant participation clinical trial , previous participation clinical trial within 30 day enter trial , previous participation trial ; 12 . Acute active chronic infection ; 13 . HCV , HBV , HIV syphilis infection ; 14 . Obstacles p.o . administration study drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>